Great frauds in history: Martin Grass’s debt binge
AS CEO of pharmacy chain Rite Aid. Martin Grass borrowed heavily to fund a string of acquisitions, then cooked the books to manage the debt, inflating profits by $1.6bn.


Martin Grass was born in 1964 and grew up in Harrisburg, Pennsylvania. After graduating from the University of Pennsylvania and doing an MBA at Cornell, he started working for Rite Aid, the pharmacy chain set up by his father, Alex, in 1962. In 1989 he was arrested for attempting to bribe a member of the Ohio state pharmacy board to step down in exchange for $33,000, although he was ultimately acquitted 15 months later when a judge ruled that the prosecution’s evidence was “circumstantial”. Despite this scandal, he took over from his father as both CEO and chairman of Rite Aid in 1995.
What was the scam?
When Martin Grass took over, Rite Aid was one of the largest pharmacy chains in America. Grass wanted to expand further, borrowing heavily to fund a string of acquisitions. In order to keep the share price soaring, despite mounting problems making repayments on this debt, Grass started to fiddle the books, using fake contracts (including with his brother-in-law’s firm) to make revenue and profits appear higher than they were. He also booked income prematurely, extended the period over which assets were depreciated and incorrectly recorded payments for medicine ordered but never collected.
What happened next?
The gap between the stated financials and reality grew so big that by October 1999 Rite Aid was forced to restate its earnings between 1997 and 1999, and lower its guidance for future profits, causing its shares to plunge by more than three-quarters. Grass was forced to resign, though it was later revealed that, even after he quit, he colluded to forge backdated documents giving several Rite Aid executives generous severance payments. He was charged with fraud in 2002 and sentenced in 2004 to eight years in jail.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Lessons for investors
Investigations revealed that Grass’s deceptions inflated profits by $1.6bn between 1997 and 1999. Rite Aid’s shares were trading at more than $50 at the start of 1999, but they fell to less than $10 a share by the end of the year, wiping more than $40bn off their value. At one point in 2009 they were trading at just $0.25. Borrowing large sums of money to fund expansion can work, but it can also create pressures on CEOs to cut corners. More generally, studies suggest that shares of firms with higher levels of debt tend to underperform.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
IMF suggests “refinements” to Rachel Reeves’s fiscal rules
The IMF has upgraded the UK’s growth forecast but wants Reeves to refine her fiscal rules to avoid unnecessary spending cuts or tax rises
-
Invest like a tortoise, not a hare to avoid market volatility
Opinion Hassan Raza, Portfolio Manager at CG Asset Management, highlights three favourite investment companies
-
Investment opportunities in the world of Coca-Cola
There is far more to Coca-Cola than just one giant firm. The companies that bottle and distribute the ubiquitous soft drink are promising investments in their own right.
-
Streaming services are the new magic money tree for investors – but for how long?
Opinion Streaming services are in full bloom and laden with profits, but beware – winter is coming, warns Matthew Lynn
-
'Pension funds shouldn't be pushed into private equity sector'
Opinion The private-equity party is over, so don't push pension funds into the sector, says Merryn Somerset Webb.
-
Greg Abel: Warren Buffett’s heir takes the throne
Greg Abel is considered a safe pair of hands as he takes centre stage at Berkshire Hathaway. But he arrives after one of the hardest acts to follow in investment history, Warren Buffett. Can he thrive?
-
Who will be the next Warren Buffett?
Opinion There won’t be another Warren Buffett. Times have changed, and the opportunities are no longer there, says Matthew Lynn.
-
Will Comstock crash – or soar?
Opinion The upside for Comstock, a solar panel-recycling and biomass-refining group, dwarfs the downside, says Dominic Frisby.
-
'As AGMs go digital, firms must offer a new form of scrutiny for shareholders'
Opinion Technology has rendered big AGM meet-ups obsolete, but the board still needs to be held to account, says Matthew Lynn
-
Unilever braces for inflation amid tariff uncertainty – what does it mean for investors?
Consumer-goods giant Unilever has made steady progress simplifying its operations. Will tariffs now cause turbulence?